Prof Stilgenbauer (Universitätsklinikum Ulm, Ulm, Germany) and Dr Jacqueline Barrientos (LIJ Medical Center, New York, USA) discuss the latest in the treatment of chronic lymphocytic leukaemia (CLL).
They consider novel agents and treatment strategies, with a particular focus on new data arising from ASCO 2015.
In particular, they discuss chemo combinations with immunology drugs such as rituximab and the use of single agents such as ibrutinib and idelalisib. They note the possible side effects associated with these new agents but ultimately recognise their positive activity, especially in 17p deletion patients.
This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).